

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-227)	AXATILIMAB
PRONUNCIATION	ax" a til' i mab
THERAPEUTIC CLAIM	Treatment of advanced solid tumors, dermatologic and fibrotic diseases

CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human colony-stimulating factor 1 receptor) (human-*Rattus norvegicus* monoclonal SNDX-6352 γ 4-chain), disulfide with human-*Rattus norvegicus* monoclonal SNDX-6352 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G4-kappa, anti-(*Homo sapiens* Macrophage colony-stimulating factor 1 receptor (Proto-oncogene c-Fms; CSF-1-R; CD115_antigen)); humanized monoclonal antibody; γ 4 heavy chain humanized (1-453) [*Homo sapiens* VH (IGHV2-70*11 (90%) –(IGHD)-IGHJ3*02 (93%)) [10.7.18] (1-126) -*Homo sapiens* IGHG4*01 {hinge[S¹⁰>P(234)]} (127-453)] (140-214')-disulfide with κ light chain humanized (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-6*01 (87%) – IGKJ4*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (232-232":235-235")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain X & X''

EVTLKESGPA	LVKPTQTLTL	TCTFSGFSLT	TYGMGVGWIR	QPPGKALEWL	50
ANLWDDDKY	YNPSLKNRLT	ISKDTSKNQV	VLTMNMDPV	DTATYYCARI	100
GPIKYPTAPY	RYFDFWQGGT	MVTVSSASTK	GPSVFPPLAPC	SRSTSESTAA	150
LGCLVKDYFP	EPVTVSWNSG	ALTSGVHTFP	AVLQSSGLYS	LSSVVTVPSS	200
SLGTKTYTCN	VDHKPSNTKV	DKRVESKYGP	PCPPCPAPEF	LGGPSVFLFP	250
PKPKDTLMIS	RTPEVTCVVV	DVSQEDPEVQ	FNWYVDGVEV	HNAKTKPREE	300
QFNSTYRVVS	VLTVLHQDWL	NGKEYKCKVS	NKGLPSSIEK	TISKAKGQPR	350
EPQVYTLPPS	QEEMTKNQVS	LTCLVKGFYP	SDIAVEWESN	GQPENNYKTT	400
PPVLDSDGSF	FLYSRLTVDK	SRWQEGNVFS	CSVMHEALHN	HYTQKSLSLS	450
LGK					503

Light chain X' & X'''

DIQMTQSPSS	LSASVGDVRT	ITCLASEDIY	DNLAWYQQKP	GKAPKLLIYY	50'
ASSLQDGVPS	RFSGSGSGTD	YTLTISSLQP	EDFATYYCLQ	DSEYPWTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-97	22"-97"	23'-88'	23'''-88'''	134'-194'	134'''-194'''	140-214'	140"-214"
153-209	153"-209"	232-232"	235-235"	267-327	267'''-327'''	373-431	373"-431"

Glycosylation sites (N)

Asn-302 Asn-302''

MOLECULAR FORMULA

C₆₅₆₈H₁₀₀₉₂N₁₆₉₆O₂₀₅₂S₄₈ (before Post-translational modifications)

MOLECULAR WEIGHT	147.18 kDa (before Post-translational modifications)
TRADEMARK	None as yet
SPONSOR	Syndax Pharmaceuticals Inc.
CODE DESIGNATIONS	SNDX-6352; UCB6352
<u>CAS</u> REGISTRY NUMBER	2155851-88-8
UNII	R96Z451BMC
WHO NUMBER	10953

gbk